Payment overview · 2025
General Payments
$1,995.29
109 reported records · 24 companies
Healthcare provider profile · identity verified
Benjamin J Levinson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · IRMO, SC · NPI 1346208865
Verified facts
What the public records show
CMS Open Payments records show Benjamin J Levinson, MD received $1,995.29 in general payments during 2025 across 109 reported records.
Novo Nordisk Inc accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $267.26 | 13.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.32 | 13.2% | 15 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $225.95 | 11.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $219.40 | 11.0% | 20 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $208.01 | 10.4% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $175.76 | 8.8% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $120.15 | 6.0% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $101.09 | 5.1% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$58.79 | 3.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.12 | 2.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.51 | 1.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.37 | 1.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.30 | 1.7% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $26.54 | 1.3% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.93 | 1.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.60 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.99 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.39 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.43 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.32 | 0.8% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $15.85 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.71 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.91 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.59 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,995.29 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $229.00 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $225.95 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.74 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $175.76 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $148.58 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $133.38 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $120.05 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.05 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $101.09 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $86.52 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.02 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $68.51 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $58.79 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $27.54 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.33 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.33 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 149 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
149 | 28 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
186 | 26 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 886 | 246 |
| Levothyroxine Sodium | Levothyroxine Sodium | 749 | 190 |
| Ezetimibe | Ezetimibe | 587 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 94 |
| Montelukast Sodium | Montelukast Sodium | 319 | 93 |
| Lisinopril | Lisinopril | 298 | 85 |
| Omeprazole | Omeprazole | 285 | 88 |
| Alprazolam | Alprazolam | 245 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 63 |
| Gabapentin | Gabapentin | 213 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 209 | 34 |
| Eliquis | Apixaban | 205 | 42 |
| Lorazepam | Lorazepam | 188 | 47 |
| Mounjaro | Tirzepatide | 186 | 26 |
| Losartan Potassium | Losartan Potassium | 177 | 50 |
| Temazepam | Temazepam | 177 | 32 |
| Trazodone Hcl | Trazodone Hcl | 166 | 47 |
| Meloxicam | Meloxicam | 160 | 59 |
| Celecoxib | Celecoxib | 159 | 47 |
| Finasteride | Finasteride | 151 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 35 |
| Farxiga | Dapagliflozin Propanediol | 149 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 33 |
| Fenofibrate | Fenofibrate | 147 | 43 |
| Furosemide | Furosemide | 147 | 45 |
| Ipratropium Bromide | Ipratropium Bromide | 143 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 52 |
| Metformin Hcl | Metformin Hcl | 140 | 39 |
| Famotidine | Famotidine | 135 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 39 |
| Jardiance | Empagliflozin | 128 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 127 | 38 |
| Tramadol Hcl | Tramadol Hcl | 126 | 44 |
| Carvedilol | Carvedilol | 124 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 20 |
| Clonazepam | Clonazepam | 123 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 120 | 40 |
| Ozempic | Semaglutide | 113 | 24 |
| Sertraline Hcl | Sertraline Hcl | 108 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 106 | 26 |
| Metformin Hcl Er | Metformin Hcl | 102 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 95 | 29 |
| Donepezil Hcl | Donepezil Hcl | 91 | 17 |
| Bupropion Xl | Bupropion Hcl | 89 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 23 |
| Potassium Chloride | Potassium Chloride | 86 | 25 |
| Torsemide | Torsemide | 85 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 22 |
| Estradiol | Estradiol | 80 | 21 |
| Armour Thyroid | Thyroid,pork | 79 | 23 |
| Simvastatin | Simvastatin | 77 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 23 |
| Atenolol | Atenolol | 72 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 25 |
| Mirtazapine | Mirtazapine | 69 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 11 |
| Clonidine Hcl | Clonidine Hcl | 67 | 18 |
| Liothyronine Sodium | Liothyronine Sodium | 67 | 14 |
| Allopurinol | Allopurinol | 66 | 21 |
| Benazepril Hcl | Benazepril Hcl | 65 | 18 |
| Synthroid | Levothyroxine Sodium | 65 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Memantine Hcl | Memantine Hcl | 64 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 38 |
| Prednisone | Prednisone | 61 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 60 | 14 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 57 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 13 |
| Fluconazole | Fluconazole | 56 | 18 |
| Labetalol Hcl | Labetalol Hcl | 56 | 12 |
| Meclizine Hcl | Meclizine Hcl | 56 | 21 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 55 | suppressed |
| Valsartan | Valsartan | 54 | 15 |
| Colchicine | Colchicine | 53 | 17 |
| Xarelto | Rivaroxaban | 53 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 19 |
| Myrbetriq | Mirabegron | 49 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 48 | 15 |
| Baclofen | Baclofen | 47 | 12 |
| Diazepam | Diazepam | 47 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 47 | suppressed |
| Sucralfate | Sucralfate | 46 | 18 |
| Methocarbamol | Methocarbamol | 45 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 14 |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Glimepiride | Glimepiride | 41 | 12 |
| Ondansetron Odt | Ondansetron | 41 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Sotalol | Sotalol Hcl | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 28 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Zaleplon | Zaleplon | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 20 |
| Zenpep | Lipase/Protease/Amylase | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Fentanyl | Fentanyl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 25 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Kerendia | Finerenone | 28 | 11 |
| Ketoconazole | Ketoconazole | 27 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | 11 |
| Ramipril | Ramipril | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Topiramate | Topiramate | 27 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Nystatin | Nystatin | 25 | 12 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Naproxen | Naproxen | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Mesalamine | Mesalamine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Spironolactone | Spironolactone | 21 | 12 |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 12 |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Niacin Er | Niacin | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 17 | suppressed |
| Piroxicam | Piroxicam | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 14 |
| Xtampza Er | Oxycodone Myristate | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Np Thyroid | Thyroid,pork | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Xiidra | Lifitegrast | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,995.29 · 109 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CLOTTRIEVER BOLD CATHETER, CREON, Cologuard Collection Kit, FARXIGA, GLYCATE, INTELLIS ADAPTIVESTIM, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, OTEZLA, Ozempic, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, Sunosi, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, XYOSTED, ZENPEP | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error